Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
CASE REPORT
Year : 2010  |  Volume : 6  |  Issue : 1  |  Page : 114-116

Follicular dendritic cell sarcoma of the neck with an aggressive and fatal course


1 Department of Medical Oncology, Cancer Institute, Chennai, India
2 Department of Pathology, Cancer Institute, Chennai, India

Date of Web Publication15-May-2010

Correspondence Address:
Sanju Cyriac
Department of Medical Oncology, Cancer Institute (WIA), 18, Sardar Patel Road, Guindy, Chennai-600 036
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.63545

Rights and Permissions
 > Abstract 

Dendritic cell neoplasms are rare malignancies described with an increased frequency. They often involve the lymph nodes, but extranodal presentations are also described. The disease often has an indolent course. Surgery is the main modality though chemotherapy and radiation have also been tried. We present here a case of a 69-year-old male diagnosed to have follicular dendritic cell sarcoma of the neck which had a rapid and fatal course inspite of chemotherapy and radiotherapy. More studies are required to assess the biology of this rare tumor.

Keywords: Dendritic cell neoplasm, immunohistochemistry, sarcoma


How to cite this article:
Cyriac S, Praveenkumar D, Majhi U, Sagar T G. Follicular dendritic cell sarcoma of the neck with an aggressive and fatal course. J Can Res Ther 2010;6:114-6

How to cite this URL:
Cyriac S, Praveenkumar D, Majhi U, Sagar T G. Follicular dendritic cell sarcoma of the neck with an aggressive and fatal course. J Can Res Ther [serial online] 2010 [cited 2019 Sep 17];6:114-6. Available from: http://www.cancerjournal.net/text.asp?2010/6/1/114/63545


 > Introduction Top


Dendritic cell neoplasms are rare malignancies arising from the antigen-presenting cells in the lymph node. The disease has an indolent course and was first described in 1986 by Monda et al. [1] Since then, nearly 200 cases have been described in the world literature. The disease is recognized more frequently with sensitive immunohistochemical markers. A standard treatment option is lacking. A recent analysis of all cases reported so far by Tommaso et al. interestingly showed that a trimodality treatment had the best outcome. [2]


 > Case Report Top


A 68-year-old gentleman presented with gradually increasing swelling in the left lower neck. He was otherwise asymptomatic. Physical examination revealed left, level IV lymph nodal swelling, 10 x 10 cm, firm, and nontender. The patient had ECOG score 1 performance status. His systemic examination was unrevealing.

Routine investigations showed normal hemogram and renal and liver function tests. Imaging of the neck was done [Figure 1]a. Biopsy of the left, level IV cervical lymph node was performed [Figure 2]. Immunohistochemical stains for CD35, vimentin, S100, CD23, and Bcl-2 were positive and those for LCA, CD3, and CD68 were negative. Ki 67 was 40-50%.

The final diagnosis was follicular dendritic cell sarcoma/tumor (FDCS/T).

Since the tumor was locally advanced with internal jugular vein thrombus, he was not considered for upfront surgery. Hence we initiated him on COP chemotherapy. There was progression after the first cycle of therapy [Figure 1]b. Hence, radiotherapy was also considered which he received in 15 fractions (200 cGy/day), but the tumor mass progressed further causing progressive tracheal compression and hypoxia and he died 2 months after the diagnosis was made.


 > Discussion Top


Dendritic cell neoplasms are being recognized with an increasing frequency. They arise from antigen-presenting cells, and occur primarily in lymph nodes [1] and also in extranodal sites. [2],[3] They were previously classified as lymphomas, sarcomas, or histiocytic neoplasms. Various classification systems have been advocated. WHO classifies dendritic cell neoplasms into five groups: Langerhans' cell histiocytosis, Langerhans' cell sarcoma, interdigitating dendritic cell sarcoma/tumor (IDCS/T), follicular dendritic cell sarcoma/tumor (FDCS/T), and dendritic cell sarcoma, not specified otherwise. [4] Pileri et al. recently proposed a classification of dendritic cell neoplasms based on morphological and immunophenotypic characteristics. [5] Feldman et al. [6] studied eight patients with both follicular lymphomas and histiocytic/dendrtic cell sarcomas. All eight H/DC tumors showed a presence of the t(14;18) either by FISH, or by PCR, and hence they suggested a common clonal origin.

FDCS/T is the most common subtype (70%) of dendritic cell neoplasms. It typically has an indolent course with a metastatic potential. [7] Median age of occurrence is 46 years, and is more common in males (male:Female, 1.4:1). De Pas et al. analyzed 184 cases of dendritic cell sarcoma reported to date. [2] A total of 60% of the cases occurred in the lymph nodes. The disease was more frequently localized at diagnosis in patients with FDCS than in those with IDCS (84.7% versus 60%). The mortality in various case series ranges from 6 to 58%. Patients with an abdominal disease have an aggressive clinical course.

Histologically, the most common patterns are storiform, fascicular, and whorled with sprinkling of small lymphocytes throughout the tumor. The neoplastic cells of FDCS/T characteristically show a spindle quality. The most common differential diagnoses are thymoma and meningioma. Immunohistochemistry has played an important role in bringing this often-misdiagnosed tumor into light. Typically, the tumor cells are positive for markers of follicular dendritic cells, i.e., CD21, CD23, and CD35. The cells are also usually positive for vimentin, fascin, HLA-DR, and EMA. They are variably positive for S100 and CD68. Markers like CD1a, lysozyme, CD34, CD3, CD79a, CD30, HMB45, and CK are consistently negative.

Since only about 200 cases have been reported worldwide, there is no consensus on the treatment of this rare disease. Surgery has remained the mainstay in localized disease. But the recurrence rate can be as high as 50%. [2] Hence adjuvant treatment is warranted. The relapse rates were better with radiotherapy compared to chemotherapy (23.1 vs. 62.5%). Interestingly, there were no relapses when a trimodality approach was used. In recurrent and advanced settings, various chemotherapeutic agents have been tried, including CHOP, ABVD, DHAP, EPOCH, ICE, cisplatin/epirubicin, with limited responses. The prognosis has been universally poor. Recently, there was a case report of using PEG liposomal doxorubicin in an adjuvant setting in a case of FDCS/T of the neck. [8]

Our patient was 68 years old, had locally advanced disease with tracheal compression, and was irresectable. Hence chemotherapy was tried but showed no response; rather, progression was present. Hence radiotherapy was also tried. The patient had progressive disease and succumbed to his illness. Such aggressive course of disease outside the abdomen is unknown. Voigt et al. presented a paratracheal FDCS/T with tracheal compression which was treated successfully with tracheal stenting, and subsequently radiotherapy with gemcitabine as the radiosensitizer. [9]

Since there are limited data on this rare disease, it is advisable to publish and share the knowledge about the presentations and treatment responses. In view of increased recognition, further researches may be initiated to assess the response to various treatment regimes.

 
 > References Top

1.Monda L, Warnke R, Rosai J. A primary lymph node malignancy with features suggestive of dendritic reticulum cell differentiation, a report of 4 cases. Am J Pathol 1986;122:562-72.  Back to cited text no. 1
[PUBMED]  [FULLTEXT]  
2.De Pas T, Spitaleri G, Pruneri G, Curigliano G, Noberasco C, Luini A, et al. Dendritic cell sarcoma: An analytic overview of the literature and presentation of original five cases. Crit Rev Oncol Hematol 2008;65:1-7.  Back to cited text no. 2
    
3.Majhi U, Shirley S, Murhekar K. Follicular dendritic cell sarcoma of oral cavity: Report of two cases. Indian J Pathol Microbiol 2007;50:545-7.  Back to cited text no. 3
[PUBMED]    
4.Jaffee ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.  Back to cited text no. 4
    
5.Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, et al. Tumours of histiocytes and accessory dendritic cells: An immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 2002;41:1-29.  Back to cited text no. 5
    
6.Feldman AL, Arber DA, Pittaluga S, Martinez A, Burke JS, Raffeld M, et al. Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: Evidence for transdifferentiation of the follicular lymphoma clone. Blood 2008;111:5433-9.  Back to cited text no. 6
    
7.Chan JK, Fletcher CD, Nayler SJ, Cooper K. Follicular dendritic cell sarcoma- clinicopathological analysis of 17 cases suggesting a malignant potential higher than currently recognized. Cancer 1997;79:294-313.  Back to cited text no. 7
[PUBMED]  [FULLTEXT]  
8.Pisani F, Marino M, Sentinelli S, Petti MC. Follicular dendritic cell sarcoma of the neck: Report of a case treated by surgical excision and COP plus (PEG)-liposomal doxorubicin. J Exp Clin Cancer Res 2008;27:33.  Back to cited text no. 8
[PUBMED]  [FULLTEXT]  
9.Voigt LP, Hmidi A, Pastores SM, Maki RG, Carlson DL, Bains MS, et al. Management Dilemmas Due to a Paratracheal Follicular Dendritic Cell Tumor. Ann Thorac Surg 2006;82:1898-1900.  Back to cited text no. 9
    


    Figures

  [Figure 1], [Figure 2]


This article has been cited by
1 Dendritic cell sarcoma: A pooled analysis including 462 cases with presentation of our case series
Caner Saygin,Didem Uzunaslan,Mustafa Ozguroglu,Mustafa Senocak,Nukhet Tuzuner
Critical Reviews in Oncology/Hematology. 2013; 88(2): 253
[Pubmed] | [DOI]
2 Follicular dendritic cell sarcoma of the pharyngeal region
Hu, T. and Wang, X. and Yu, C. and Yan, J. and Zhang, X. and Li, L. and Li, X. and Zhang, L. and Wu, J. and Ma, W. and Li, W. and Wang, G. and Zhao, W. and Gao, X. and Zhang, D. and Zhang, M.
Oncology Letters. 2013; 5(5): 1467-1476
[Pubmed]
3 Dendritic cell tumor in a salivary gland lymph node: a rare differential diagnosis of salivary gland neoplasms
Sebastian P Schraven,Stefan K Plontke,Roland Syha,Falko Fend,Hartwig Wolburg,Patrick Adam
Diagnostic Pathology. 2011; 6(1): 94
[Pubmed] | [DOI]
4 Dendritic cell tumor in a salivary gland lymph node: A rare differential diagnosis of salivary gland neoplasms
Schraven, S.P., Plontke, S.K., Syha, R., Fend, F., Wolburg, H., Adam, P.
Diagnostic Pathology. 2011; 6(1): art-94
[Pubmed]
5 Clinicopathologic features of hepatic follicular dendritic cell sarcoma
Huang, H.-J., Yu, Y.-H., Zheng, Z.-Y.
World Chinese Journal of Digestology. 2010; 18(33): 3520-3526
[Pubmed]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  >Abstract>Introduction>Case Report>Discussion>Article Figures
  In this article
>References

 Article Access Statistics
    Viewed3132    
    Printed135    
    Emailed0    
    PDF Downloaded347    
    Comments [Add]    
    Cited by others 5    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]